age1 — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.